Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BG-60366 |
| Synonyms | |
| Therapy Description |
BG-60366 is a chimeric degradation activation compound (CDAC) comprising a ligand that binds to E3 ubiquitin ligase linked to a ligand targeting mutant EGFR, which potentially induces proteasome-mediated degradation of mutant EGFR and decreased growth of tumor cells (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BG-60366 | BG60366|BG 60366 | EGFR Inhibitor (Pan) 63 | BG-60366 is a chimeric degradation activation compound (CDAC) comprising a ligand that binds to E3 ubiquitin ligase linked to a ligand targeting mutant EGFR, which potentially induces proteasome-mediated degradation of mutant EGFR and decreased growth of tumor cells (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06685718 | Phase I | BG-60366 | A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer | Recruiting | USA | NZL | ITA | ESP | AUS | 2 |